91Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Austria
Neuroscience Intelligence
Austria neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #23 of 50 · Data maturity A · Research score 37.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
28Recruiting trials
81Publications
68Institutions
Executive interpretation
Austria ranks #23 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Medical University of Vienna72 recruiting
Boehringer Ingelheim60 recruiting
Merck Sharp & Dohme LLC53 recruiting
Hoffmann-La Roche53 recruiting
Bayer33 recruiting
NORCE Norwegian Research Centre AS21 recruiting
Newron Pharmaceuticals SPA20 recruiting
JANSSEN Alzheimer Immunotherapy Research & Development, LLC20 recruiting
AbbVie20 recruiting
Novartis Pharmaceuticals21 recruiting
Disease activity
Parkinsons22trials
Epilepsy11trials
Alzheimers9trials
Neuro Oncology5trials
Depression5trials
Stroke5trials
Other Neurology3trials
Schizophrenia3trials
Adhd3trials
Multiple Sclerosis3trials
Research institutions
Konrad Lorenz Institute for Evolution and Cognition ResearchOpenAlexlinked institution
Innsbruck Medical UniversityOpenAlexlinked institution
Universität InnsbruckOpenAlexlinked institution
Salzburger LandesklinikenOpenAlexlinked institution
FH JOANNEUM University of Applied SciencesOpenAlexlinked institution
Ludwig Boltzmann Institute Digital Health and Patient SafetyOpenAlexlinked institution
Klinik HietzingOpenAlexlinked institution
University of SalzburgOpenAlexlinked institution
European Society of RadiologyOpenAlexlinked institution
Vienna BiocenterOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07586150Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)NOT_YET_RECRUITING
NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07107074Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCEACTIVE_NOT_RECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06830720A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRECRUITING
NCT06803706Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic CommunityRECRUITING
Research evidence trail
PUBMEDLinks between personality functioning and post-traumatic stress disorder symptoms: a network analysis.2026-12-01
PUBMEDBefore depression in diabetes is attributed to polyneuropathy, all other causes must be ruled out.2026-12-01
PUBMEDAssessment of treatment response in recurrent medulloblastoma using craniospinal MRI.2026-11-01
PUBMEDIntratumoral desmoplastic stroma in carcinoma brain metastases harbors stromal cells with a cancer-associated fibroblast (CAF)-like immunophenotype.2026-10-07
PUBMEDImpaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives.2026-10-06
PUBMEDLong-Term Use of Tiapride and Tetrabenazine in Huntington's Disease: A 25-Year Retrospective Single-Center Analysis.2026-10-01
PUBMEDRule Out Myelitis Prior to Cutting Into a Child's Back Because of Progressive Tetraparesis.2026-10-01
PUBMEDThe amygdala in bipolar disorder: A cross-sectional study examining the relevance of structural alterations of amygdala subfields for cognitive functioning in patients with bipolar disorder.2026-10-01
PUBMEDBefore glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 can be recommended for identifying cerebral lesions in mild traumatic brain injury, all influencing factors must be taken into account.2026-10-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.